CDC Directs States to Prepare For COVID-19 Vaccine

A coronavirus Vaccine could be ready by early November.

Photo from

The Center for Disease Control and Prevention has informed states to prepare to release a Coronavirus vaccine by as early as late October to early November. The limited quantity of vaccines to be released would first go to frontline health workers and others who have a higher risk of contracting the virus.
Currently there are two vaccines under examination with the possibility of being released soon. The vaccines are being referred to as Vaccine A and Vaccine B. According toThe New York Times handling instructions for the vaccines are similar to a couple of other vaccines that they are tracking on their Coronavirus Vaccine Tracker, such as storage temperature and days between dosages.
Pharmaceutical companies such as Pfizer from New York, BioNTech from Germany and Fosun Pharma from China worked together to develop an mRNA vaccine. This was moved to the second and third phases of testing which, according to The New York Times, means the vaccine has been given to thousands of people to see if it protects from the Virus. This also means that it has passed the first phase ensuring that it is safe to be used on humans.
In August, Pfizer had said they were on track for regulatory review by October. The U.S. Government has signed a $1.9 billion contract for 100 million doses to be delivered by December. The deal was signed as part of Operation Warp Speed, the Trump administration’s effort to accelerate development and production of vaccines and treatments to combat the pandemic.
Moderna is the other company which is showing signs of releasing a vaccine for trial in the U.S.. The New York Times also said that, “In partnership with National Institutes of Health, [Moderna] found that the vaccine protects monkeys from the coronavirus. In March, the company put the first Covid-19 vaccine into human trials, which yielded promising results.”
Moderna will expand their research in phase three by injecting 30,000 people with the vaccine. If it proves to work well, the U.S. will give $1.5 billion for 100 million doses of the vaccine.

There are many other companies from around the world going through trials and testing phases, including a vaccine from Gamaleya Research Institute in Russia, Sinovac in Indonesia and various others are circulating around Europe.